Market reviews 2016

Market review on human pharmaceuticals 2016

Published on 8 February 2017

Finland is the most important individual market for Orion, generating about one-third of the total net sales. According to IMS Health statistics, Finnish wholesale of human pharmaceuticals in 2016 was up by 4% on the previous year at EUR 2,320 (2,239) million. Orion was able to increase its sales faster than market growth, and strengthened its position as leader in marketing pharmaceuticals in Finland. According to statistics collected by IMS Health, Orion’s wholesale of human pharmaceuticals in Finland in 2016 amounted to EUR 299 (270) million, up by 11% compared with the previous year. Orion’s market share of Finnish pharmaceuticals markets was 13% (12%).

The most important individual therapy area for Orion is still the treatment of Parkinson’s disease. Orion’s branded Parkinson’s drugs containing entacapone (Stalevo^®, Comtess^® and Comtan^®) account for slightly over 10% of the Group’s net sales.

Total sales of all Parkinson’s drugs:

Total sales of Orion’s branded Parkinson’s drugs:

Sales of Orion’s branded Parkinson’s drugs decreased in Europe due to commencement of generic competition. Sales increased in Japan, mainly due to growth in Stalevo, which was launched in that market in 2015.

According to IMS Health pharmaceutical sales statistics, in Europe total sales of the most common intravenous anaesthetics and intensive care sedatives (propofol, midazolam, remifentanil and dexmedetomidine) in the 12-month period ending in September 2016 were up by 2% at EUR 527 (518) million. According to IMS Health pharmaceutical sales statistics, sales of Orion’s Dexdor^® intensive care sedative (dexmedetomidine) were up by 28% at EUR 44 (34) million in Europe.

Published on 25 October 2016

Finland is the most important individual market for Orion, generating about one-third of the total net sales. According to IMS Health statistics, Finnish wholesale of human pharmaceuticals in January–September 2016 was up by 4% on the previous year at EUR 1,680 (1,620) million. Orion was able to increase its sales faster than market growth, and strengthened its position as leader in marketing pharmaceuticals in Finland. According to statistics collected by IMS Health, Orion’s wholesale of human pharmaceuticals in Finland in January–September 2016 amounted to EUR 217 (195) million, up by 12% compared with the previous year. Orion’s market share of Finnish pharmaceuticals markets was 13% (12%).

The most important individual therapy area for Orion is still the treatment of Parkinson’s disease. Orion’s branded Parkinson’s drugs containing entacapone (Stalevo^®, Comtess^® and Comtan^®) account for under 15% of the Group’s net sales.

Total sales of all Parkinson’s drugs:

The five largest European markets for Parkinson’s disease drugs were Germany, the United Kingdom, France, Spain and Italy.

Total sales of all Parkinson’s drugs containing entacapone:

Total sales of Orion’s branded Parkinson’s drugs:

Sales of Orion’s branded Parkinson’s drugs decreased in Europe due to commencement of generic competition. Sales increased in Japan mainly because Stalevo was launched in that market during 2015. The market share of Orion’s branded Parkinson’s drugs was 1% in the United States, on average 9% in the five largest European markets and 12% in Japan.

According to IMS Health pharmaceutical sales statistics, in Europe total sales of the most common intravenous anaesthetics and intensive care sedatives (propofol, midazolam, remifentanil and dexmedetomidine) in the 12-month period ending in June 2016 were up by 4% at EUR 530 (511) million. According to IMS Health pharmaceutical sales statistics, sales of Orion’s Dexdor^® intensive care sedative (dexmedetomidine) were up by 26% at EUR 41 (32) million in Europe.

Published on 19 July 2016

Finland is the most important individual market for Orion, generating about one-third of the total net sales. According to IMS Health statistics, Finnish wholesale of human pharmaceuticals in January–June 2016 was up by 3% on the previous year at EUR 1,106 (1,071) million. Orion was able to increase its sales faster than market growth, and strengthened its position as leader in marketing pharmaceuticals in Finland. According to statistics collected by IMS Health, Orion’s wholesale of human pharmaceuticals in Finland in January–June 2016 amounted to EUR 143 (129) million, up by 11% compared with the previous year. Orion’s market share of Finnish pharmaceuticals markets was 13% (12%).

The most important individual therapy area for Orion is still the treatment of Parkinson’s disease. Orion’s branded Parkinson’s drugs containing entacapone (Stalevo^®, Comtess^® and Comtan^®) account for under 15% of the Group’s net sales.

Total sales of all Parkinson’s drugs:

The five largest European markets for Parkinson’s disease drugs were Germany, the United Kingdom, France, Spain and Italy.

Total sales of all Parkinson’s drugs containing entacapone:

Total sales of Orion’s branded Parkinson’s drugs:

Salesof Orion’s branded Parkinson’s drugs decreased in Europe due to commencement of generic competition. Sales increased in Japan mainly because Stalevo was launched in that market during 2015. The market share of Orion’s branded Parkinson’s drugs was 2% in the United States, on average 9% in the five largest European markets and 12% in Japan.

According to IMS Health pharmaceutical sales statistics, in Europe total sales of the most common intravenous anaesthetics and intensive care sedatives (propofol, midazolam, remifentanil and dexmedetomidine) in the 12-month period ending in March 2016 were up by 4% at EUR 527 (507) million. According to IMS Health pharmaceutical sales statistics, sales of Orion’s Dexdor^® intensive care sedative (dexmedetomidine) were up by 27% at EUR 38 (30) million in Europe.

Published on 27 April 2016

Finland is the most important individual market for Orion, generating about one-third of the total net sales. According to IMS Health statistics, Finnish wholesale of human pharmaceuticals in January–March 2016 was up by 2% on the previous year at EUR 534 (521) million. Orion was able to increase its sales faster than market growth, and strengthened its position as leader in marketing pharmaceuticals in Finland. According to statistics collected by IMS Health, Orion’s wholesale of human pharmaceuticals in Finland in January–March 2016 amounted to EUR 69 (63) million, up by 11% compared with the previous year. Orion’s market share of Finnish pharmaceuticals markets was 13% (12%).

The most important individual therapy area for Orion is still the treatment of Parkinson’s disease. Orion’s branded Parkinson’s drugs containing entacapone (Stalevo^®, Comtess^® and Comtan^®) account for under 15% of the Group’s net sales.

Total sales of all Parkinson’s drugs:

The five largest European markets for Parkinson’s disease drugs were Germany, the United Kingdom, France, Spain and Italy.

Total sales of all Parkinson’s drugs containing entacapone:

Total sales of Orion’s branded Parkinson’s drugs:

Salesof Orion’s branded Parkinson’s drugs decreased in Europe due to commencement of generic competition. Sales increased in Japan mainly because Stalevo was launched in that market during 2015. The market share of Orion’s branded Parkinson’s drugs was 2% in the United States, on average 10% in the five largest European markets and 12% in Japan.

According to IMS Health pharmaceutical sales statistics, in Europe total sales of the most common intravenous anaesthetics and intensive care sedatives (propofol, midazolam, remifentanil and dexmedetomidine) in the 12-month period ending in December 2015 were up by 5% at EUR 525 (501) million. According to IMS Health pharmaceutical sales statistics, sales of Orion’s Dexdor^® intensive care sedative (dexmedetomidine) were up by 30% at EUR 36 (28) million in Europe.